328 related articles for article (PubMed ID: 23996115)
1. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
2. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
[TBL] [Abstract][Full Text] [Related]
3. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
Zhao J; Cao Y; Jusko WJ
Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
[TBL] [Abstract][Full Text] [Related]
4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
5. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
6. Applications of minimal physiologically-based pharmacokinetic models.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):711-23. PubMed ID: 23179857
[TBL] [Abstract][Full Text] [Related]
7. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
8. An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.
Chadha GS; Morris ME
AAPS J; 2015 Nov; 17(6):1464-74. PubMed ID: 26276217
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.
Fronton L; Pilari S; Huisinga W
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):87-107. PubMed ID: 24493102
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
[TBL] [Abstract][Full Text] [Related]
12. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
13. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
Maas BM; Cao Y
MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
[TBL] [Abstract][Full Text] [Related]
14. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
15. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
16. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
17. Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.
Elmeliegy M; Lowe P; Krzyzanski W
AAPS J; 2014 Jul; 16(4):810-42. PubMed ID: 24871341
[TBL] [Abstract][Full Text] [Related]
18. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
19. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.
Hardiansyah D; Ng CM
Pharm Res; 2018 Feb; 35(3):47. PubMed ID: 29411151
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]